Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treatment of HCC in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with intermediate and advanced/relapsed HCC representing the oncology societies of Taiwan (TOS), China (CSCO), India (ISMPO) Japan (JSMO), Korea (KSMO), Malaysia (MOS) and Singapore (SSO). The voting was based on scientific evidence, and was independent of the current treatment practices, the drug availability and reimbursement situations in the individual participating Asian countries.

Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis

“…In the REFLECT trial, lenvatinib showed noninferiority to sorafenib in overall survival (OS), with a clinically meaningful improvement in progression-free survival (PFS), and objective response rate (ORR) [11]. Current international guidelines recommend lenvatinib as the first-line therapy for patients with advanced HCC [12-15]. Real-world evidence is important in HCC because of the discrepancies in patient characteristics between clinical trials and daily practice.…”

Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib

“…In this study, 55 (55%) patients were in the intermediate BCLC stage B and received systemic lenvatinib therapy. The global standard of care recommended for intermediate BCLC stage B is transcatheter arterial chemoembolization (TACE) 38,39 . However, recent clinical studies have shown that lenvatinib treatment for patients with intermediate-stage HCC who present with beyond up-to-seven criteria and have Child-Pugh class A prolonged PFS and OS 40,41 .…”

Ultrasound-mediated delivery of RGD-conjugated nanobubbles loaded with fingolimod and superparamagnetic iron oxide nanoparticles: targeting hepatocellular carcinoma and enhancing magnetic resonance imaging

“…1,2 The insidious onset and rapid development of HCC are oen accompanied by the metastasis of cancer cells inside and/or outside the liver, which brings great challenges to the diagnosis and treatment of HCC at the early stage. [3][4][5] Therefore, the development of drug delivery platforms that effectively target tumors, accurately release multi-drugs at desired locations, as well as simultaneously perform diagnosis and treatment has become the focus of cancer research in recent years.…”